See also this year's filing and all EDGAR filings for this company.
PDF Report 0001534120_2019_Avalo_Therapeutics_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.00066680434822772, 'aggregate_val': 57606657, 'exp_sum': 57645095, 'exp_to_value': {'CostOfGoodsAndServicesSold': 7478262, 'SellingGeneralAndAdministrativeExpense': 10676881, 'ResearchAndDevelopmentExpense': 5786635, 'remainder_Expenses': 33703317}} |
Graph
Absolute values for 0001534120, Avalo Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 21,931,893 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 47,650,591 |
| 2 | PropertyPlantAndEquipmentNet | 586,512 |
| 3 | remainder_Assets | 81,725 |
| 4 | LiabilitiesCurrent | 26,216,579 |
| 5 | LiabilitiesNoncurrent | 14,713,399 |
| 6 | remainder_Liabilities | 8,412,995 |
| 7 | CostOfGoodsAndServicesSold | 7,478,262 |
| 8 | SellingGeneralAndAdministrativeExpense | 10,676,881 |
| 9 | ResearchAndDevelopmentExpense | 5,786,635 |
| 10 | remainder_Expenses | 33,664,879 |
| 11 | remainder_Revenues | 18,326,801 |
| 12 | remainder_NetIncome | -772,954 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 70,250,721 |
| 1 | Liabilities | 49,342,973 |
| 2 | Expenses | 57,606,657 |
| 3 | Revenues | 18,326,801 |
| 4 | StockholdersEquity | 20,907,748 |
| 5 | NetIncome | -40,052,810 |
| 6 | ComprehensiveNetIncome | -40,052,810 |
| 7 | BaseVar | 98,150,053 |
| 8 | EconomicCapitalRatio | -0.0684 |
Edgar->Model Mapping
Feature Distribution
Change over Time
